Single-cell profiling of PBMCs reveals distinct immune signatures associated with methotrexate response in rheumatoid arthritis

Rheumatoid arthritis (RA) is a systemic autoimmune disease with complex pathogenesis and clinical heterogeneity. Methotrexate (MTX) is the cornerstone treatment for RA, yet 30–40% of patients exhibit an inadequate response. This study aims to systematically compare the differences in immune characteristics between treatment-naïve patients and those treated with MTX, as well as between MTX responders and non-responders to identify biomarkers of MTX response. We conducted single-cell RNA sequencing (scRNA-seq) on peripheral blood mononuclear cells (PBMCs) from treatment-naïve (TN), treatment success (TS), and treatment failure (TF) RA patients. We focused on the impact of methotrexate treatment on the proportion of immune cells and explored the differences between the MTX response group and non-response group. The scRNA-seq data revealed that MTX can broadly attenuate lymphocyte proliferation and rebalanced proinflammatory T helper subsets. For MTX responders and non-responders, the TS group displayed enhanced type I interferon (IFN-I) signaling and elevated proportions of regulatory T cells (Tregs), whereas the TF group demonstrated activation of TNFα pathways and expansion of cytotoxic NK-CD56dim-CD16hi-IFNG, which could recruit classical monocytes. Our study unveils distinct immune mechanisms underlying MTX response and identifies FKBP5 as a potential prognostic biomarker for personalized RA therapy. Our research findings indicate that MTX plays a key role in rebalancing the proportion of immune cells, including reducing the proportion of proinflammatory Th1/Th17 cells, conventional dendritic cells (cDCs) and plasma cells and increasing the proportion of Th2 cells and Tregs. Additionally, we found that compared with the TS group, the TF group had a stronger TNFα response score in myeloid cells, whereas myeloid cells in the TS group exhibited a higher type I interferon (IFN-I) response score.

Authors

Institutions

Publication Details

Journal
Arthritis Research & Therapy
Published
2026-11-16
DOI
https://doi.org/10.1186/s13075-026-03948-x
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Single-cell profiling of PBMCs reveals distinct immune signatures associated with methotrexate response in rheumatoid arthritis

Fan Bai, Linmang Qin, Lei Pei, Qian Wang et al.
3 links
Arthritis Research & Therapy
Rheumatoid Arthritis Research and Therapies
article

Single-cell profiling of PBMCs reveals distinct immune signatures associated with methotrexate response in rheumatoid arthritis

Fan Bai, Linmang Qin, Lei Pei, Qian Wang, Shangyi Jin, Yafang Deng, Xinping Tian
article en

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease with complex pathogenesis and clinical heterogeneity. Methotrexate (MTX) is the cornerstone treatment for RA, yet 30–40% of patients exhibit an inadequate response. This study aims to systematically compare the differences in immune characteristics between treatment-naïve patients and those treated with MTX, as well as between MTX responders and non-responders to identify biomarkers of MTX response. We conducted single-cell RNA sequencing (scRNA-seq) on peripheral blood mononuclear cells (PBMCs) from treatment-naïve (TN), treatment success (TS), and treatment failure (TF) RA patients. We focused on the impact of methotrexate treatment on the proportion of immune cells and explored the differences between the MTX response group and non-response group. The scRNA-seq data revealed that MTX can broadly attenuate lymphocyte proliferation and rebalanced proinflammatory T helper subsets. For MTX responders and non-responders, the TS group displayed enhanced type I interferon (IFN-I) signaling and elevated proportions of regulatory T cells (Tregs), whereas the TF group demonstrated activation of TNFα pathways and expansion of cytotoxic NK-CD56dim-CD16hi-IFNG, which could recruit classical monocytes. Our study unveils distinct immune mechanisms underlying MTX response and identifies FKBP5 as a potential prognostic biomarker for personalized RA therapy. Our research findings indicate that MTX plays a key role in rebalancing the proportion of immune cells, including reducing the proportion of proinflammatory Th1/Th17 cells, conventional dendritic cells (cDCs) and plasma cells and increasing the proportion of Th2 cells and Tregs. Additionally, we found that compared with the TS group, the TF group had a stronger TNFα response score in myeloid cells, whereas myeloid cells in the TS group exhibited a higher type I interferon (IFN-I) response score.

Arthritis Research & Therapy
Peking University (CN), Peking Union Medical College Hospital (CN), Center for Life Sciences (CN)
National Key Research and Development Program of China
Good health and well-being
Rheumatoid Arthritis Research and Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon